Cargando…
Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy
BACKGROUND: Calcitriol antiproliferative effects include inhibition of the oncogenic ether-à-go-go-1 potassium channel (Eag1) expression, which is necessary for cell cycle progression and tumorigenesis. Astemizole, a new promising antineoplastic drug, targets Eag1 by blocking ion currents. Herein, w...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440370/ https://www.ncbi.nlm.nih.gov/pubmed/22984610 http://dx.doi.org/10.1371/journal.pone.0045063 |
_version_ | 1782243146148610048 |
---|---|
author | García-Quiroz, Janice García-Becerra, Rocío Barrera, David Santos, Nancy Avila, Euclides Ordaz-Rosado, David Rivas-Suárez, Mariana Halhali, Ali Rodríguez, Pamela Gamboa-Domínguez, Armando Medina-Franco, Heriberto Camacho, Javier Larrea, Fernando Díaz, Lorenza |
author_facet | García-Quiroz, Janice García-Becerra, Rocío Barrera, David Santos, Nancy Avila, Euclides Ordaz-Rosado, David Rivas-Suárez, Mariana Halhali, Ali Rodríguez, Pamela Gamboa-Domínguez, Armando Medina-Franco, Heriberto Camacho, Javier Larrea, Fernando Díaz, Lorenza |
author_sort | García-Quiroz, Janice |
collection | PubMed |
description | BACKGROUND: Calcitriol antiproliferative effects include inhibition of the oncogenic ether-à-go-go-1 potassium channel (Eag1) expression, which is necessary for cell cycle progression and tumorigenesis. Astemizole, a new promising antineoplastic drug, targets Eag1 by blocking ion currents. Herein, we characterized the interaction between calcitriol and astemizole as well as their conjoint antiproliferative action in SUM-229PE, T-47D and primary tumor-derived breast cancer cells. METHODOLOGY/PRINCIPAL FINDINGS: Molecular markers were studied by immunocytochemistry, Western blot and real time PCR. Inhibitory concentrations were determined by dose-response curves and metabolic activity assays. At clinically achievable drug concentrations, synergistic antiproliferative interaction was observed between calcitriol and astemizole, as calculated by combination index analysis (CI <1). Astemizole significantly enhanced calcitriol’s growth-inhibitory effects (3–11 folds, P<0.01). Mean IC(20) values were 1.82±2.41 nM and 1.62±0.75 µM; for calcitriol (in estrogen receptor negative cells) and astemizole, respectively. Real time PCR showed that both drugs alone downregulated, while simultaneous treatment further reduced Ki-67 and Eag1 gene expression (P<0.05). Astemizole inhibited basal and calcitriol-induced CYP24A1 and CYP3A4 mRNA expression (cytochromes involved in calcitriol and astemizole degradation) in breast and hepatoma cancer cells, respectively, while upregulated vitamin D receptor (VDR) expression. CONCLUSIONS/SIGNIFICANCE: Astemizole synergized calcitriol antiproliferative effects by downregulating CYP24A1, upregulating VDR and targeting Eag1. This study provides insight into the molecular mechanisms involved in astemizole-calcitriol combined antineoplastic effect, offering scientific support to test both compounds in combination in further preclinical and clinical studies of neoplasms expressing VDR and Eag1. VDR-negative tumors might also be sensitized to calcitriol antineoplastic effects by the use of astemizole. Herein we suggest a novel combined adjuvant therapy for the management of VDR/Eag1-expressing breast cancer tumors. Since astemizole improves calcitriol bioavailability and activity, decreased calcitriol dosing is advised for conjoint administration. |
format | Online Article Text |
id | pubmed-3440370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34403702012-09-14 Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy García-Quiroz, Janice García-Becerra, Rocío Barrera, David Santos, Nancy Avila, Euclides Ordaz-Rosado, David Rivas-Suárez, Mariana Halhali, Ali Rodríguez, Pamela Gamboa-Domínguez, Armando Medina-Franco, Heriberto Camacho, Javier Larrea, Fernando Díaz, Lorenza PLoS One Research Article BACKGROUND: Calcitriol antiproliferative effects include inhibition of the oncogenic ether-à-go-go-1 potassium channel (Eag1) expression, which is necessary for cell cycle progression and tumorigenesis. Astemizole, a new promising antineoplastic drug, targets Eag1 by blocking ion currents. Herein, we characterized the interaction between calcitriol and astemizole as well as their conjoint antiproliferative action in SUM-229PE, T-47D and primary tumor-derived breast cancer cells. METHODOLOGY/PRINCIPAL FINDINGS: Molecular markers were studied by immunocytochemistry, Western blot and real time PCR. Inhibitory concentrations were determined by dose-response curves and metabolic activity assays. At clinically achievable drug concentrations, synergistic antiproliferative interaction was observed between calcitriol and astemizole, as calculated by combination index analysis (CI <1). Astemizole significantly enhanced calcitriol’s growth-inhibitory effects (3–11 folds, P<0.01). Mean IC(20) values were 1.82±2.41 nM and 1.62±0.75 µM; for calcitriol (in estrogen receptor negative cells) and astemizole, respectively. Real time PCR showed that both drugs alone downregulated, while simultaneous treatment further reduced Ki-67 and Eag1 gene expression (P<0.05). Astemizole inhibited basal and calcitriol-induced CYP24A1 and CYP3A4 mRNA expression (cytochromes involved in calcitriol and astemizole degradation) in breast and hepatoma cancer cells, respectively, while upregulated vitamin D receptor (VDR) expression. CONCLUSIONS/SIGNIFICANCE: Astemizole synergized calcitriol antiproliferative effects by downregulating CYP24A1, upregulating VDR and targeting Eag1. This study provides insight into the molecular mechanisms involved in astemizole-calcitriol combined antineoplastic effect, offering scientific support to test both compounds in combination in further preclinical and clinical studies of neoplasms expressing VDR and Eag1. VDR-negative tumors might also be sensitized to calcitriol antineoplastic effects by the use of astemizole. Herein we suggest a novel combined adjuvant therapy for the management of VDR/Eag1-expressing breast cancer tumors. Since astemizole improves calcitriol bioavailability and activity, decreased calcitriol dosing is advised for conjoint administration. Public Library of Science 2012-09-12 /pmc/articles/PMC3440370/ /pubmed/22984610 http://dx.doi.org/10.1371/journal.pone.0045063 Text en © 2012 García-Quiroz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article García-Quiroz, Janice García-Becerra, Rocío Barrera, David Santos, Nancy Avila, Euclides Ordaz-Rosado, David Rivas-Suárez, Mariana Halhali, Ali Rodríguez, Pamela Gamboa-Domínguez, Armando Medina-Franco, Heriberto Camacho, Javier Larrea, Fernando Díaz, Lorenza Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title | Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title_full | Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title_fullStr | Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title_full_unstemmed | Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title_short | Astemizole Synergizes Calcitriol Antiproliferative Activity by Inhibiting CYP24A1 and Upregulating VDR: A Novel Approach for Breast Cancer Therapy |
title_sort | astemizole synergizes calcitriol antiproliferative activity by inhibiting cyp24a1 and upregulating vdr: a novel approach for breast cancer therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440370/ https://www.ncbi.nlm.nih.gov/pubmed/22984610 http://dx.doi.org/10.1371/journal.pone.0045063 |
work_keys_str_mv | AT garciaquirozjanice astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT garciabecerrarocio astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT barreradavid astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT santosnancy astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT avilaeuclides astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT ordazrosadodavid astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT rivassuarezmariana astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT halhaliali astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT rodriguezpamela astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT gamboadominguezarmando astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT medinafrancoheriberto astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT camachojavier astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT larreafernando astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy AT diazlorenza astemizolesynergizescalcitriolantiproliferativeactivitybyinhibitingcyp24a1andupregulatingvdranovelapproachforbreastcancertherapy |